Commonwealth Serum Laboratories (CSL), an Australian biotechnology company and the world’s second-biggest flu vaccine manufacturer, has agreed to pay $312 million ($US200 million) to use groundbreaking mRNA vaccine technology from a U.S. company. The vaccine manufacturer announced on Nov. 2 that it had licenced the new technology with Arcturus Therapeutics, an American mRNA medicines biotechnology company….

The University of Queensland announced its collaboration with Moderna to use mRNA research for vaccine development of diseases that pose risks of causing future pandemics. The university previously collaborated with CSL—a major biotechnology firm now responsible for the manufacturing of the AstraZeneca vaccine in Australia—on producing a COVID-19 vaccine. The deal was called off, however,…

The first cell-based Influenza vaccine in Australia has been approved for use in adults and children aged two years and older. In a statement written to the Epoch Times, the Therapeutic Goods Administration (TGA) wrote that the Flucelvax Quad vaccine is the first and only cell-based flu vaccine available in Australia and approved for Australians…